PMID- 19760032
OWN - NLM
STAT- MEDLINE
DCOM- 20101025
LR  - 20220331
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 122
IP  - 1
DP  - 2010 Jul
TI  - Unfavourable clinicopathologic features and low response rate to systemic 
      adjuvant therapy: results with regard to poor survival in young Chinese breast 
      cancer patients.
PG  - 95-104
LID - 10.1007/s10549-009-0537-4 [doi]
AB  - The prognostic factors of young breast cancer patients (BCPs) are still 
      controversial. This study is aimed at evaluating the prognosis of young BCPs by 
      characteristics and treatment response. We analysed the data on 2,593 operable 
      BCPs age <or=50 years who were treated in the Cancer Hospital of Fudan 
      University, Shanghai, China between 1990 and 2004. The overall survival and 
      recurrence/metastasis-free survival were compared. In the study, 782 patients 
      (30.2%) were <or=40 years, and 1,811 (69.8%) were 41-50 years old at their 
      primary diagnosis. BCPs <or=40 years presented more unfavourable features than 
      the 41-50 years BCPs (P < 0.05). They were more likely to experience death (P < 
      0.001) and recurrence/metastasis events (P < 0.001) even when they underwent the 
      same adjuvant therapy in parallel with their counterparts (P < 0.05). In a 
      multivariate analysis, age was an independent predictive factor for RFS (HR = 
      0.26, 95% CI = 0.44-0.89, P = 0.009) but not for OS (P > 0.05). Higher TNM stage 
      and chemotherapy, but not HER2/neu over-expression, were predictive factors for 
      young Chinese BCPs. The characteristics of breast cancer are more aggressive in 
      young Chinese BCPs. Their prognostic factors are obviously different from those 
      of the elder group. Current therapy was not as effective for them.
FAU - Tang, Li-Chen
AU  - Tang LC
AD  - Department of Oncology, Shanghai Medical College, Breast Cancer Institute, Cancer 
      Hospital/Cancer Institute, Fudan University, 270 Dong'an Road, 200032 Shanghai, 
      People's Republic of China.
FAU - Yin, Wen-Jin
AU  - Yin WJ
FAU - Di, Gen-Hong
AU  - Di GH
FAU - Shen, Zhen-Zhou
AU  - Shen ZZ
FAU - Shao, Zhi-Ming
AU  - Shao ZM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090917
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Breast Neoplasms/drug therapy/*mortality/pathology/radiotherapy/surgery
MH  - Carcinoma/drug therapy/*mortality/pathology/radiotherapy/surgery
MH  - Chemotherapy, Adjuvant
MH  - China/epidemiology
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Mastectomy
MH  - Middle Aged
MH  - Ovariectomy
MH  - Patient Selection
MH  - Proportional Hazards Models
MH  - Radiotherapy, Adjuvant
EDAT- 2009/09/18 06:00
MHDA- 2010/10/26 06:00
CRDT- 2009/09/18 06:00
PHST- 2009/03/18 00:00 [received]
PHST- 2009/08/27 00:00 [accepted]
PHST- 2009/09/18 06:00 [entrez]
PHST- 2009/09/18 06:00 [pubmed]
PHST- 2010/10/26 06:00 [medline]
AID - 10.1007/s10549-009-0537-4 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2010 Jul;122(1):95-104. doi: 10.1007/s10549-009-0537-4. 
      Epub 2009 Sep 17.